Morphic

$30.84
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.33 (+4.51%) Today

$0.00 (0.00%) As of 4:00 PM EST after-hours

Why Robinhood?

You can buy or sell Morphic and other stocks, options, and ETFs commission-free!

About MORF

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA. The listed name for MORF is Morphic Holding, Inc. Common Stock.

CEO

Praveen P. Tipirneni

Employees

Headquarters

Waltham, Massachusetts

Founded

2014

Market Cap

959.90M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

110.59K

High Today

$31.91

Low Today

$29.43

Open Price

$29.91

Volume

105.81K

52 Week High

$31.91

52 Week Low

$9.90

Collections

Research And Development

Therapy

Pharmaceutical

2019 IPO

MORF Earnings

-$4.73

-$3.03

-$1.34

$0.36

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Estimated

— per share

Actual

$0.17 per share